§ Mr. BarronTo ask the Secretary of State for Health (1) what plans he has to review the prescribing recommendations in the Prodigy pilot study in respect of people with epilepsy who experience adverse reactions to no-branded medicines; and if he will make a statement; [3292]
(2) what representations he has received from (a) pharmaceutical manufacturers, (b) patient groups and (c) general practitioners regarding the prescribing recommendations in the Prodigy pilot study; [3296]
(3) what plans he has to review the prescribing recommendations in the Prodigy pilot study relating to the treatment of hypertension; and if he will make a statement; [3289]
(4) what plans he has to review the prescribing recommendations in the Prodigy pilot study in respect of people with diabetes requiring animal-based insulins; and if he will make a statement. [3291]
§ Mr. MaloneThe Prodigy project encourages comment from general practitioners taking part in the trial. Following publication of the guidelines used for phase 1 of the project, we have received a number of detailed comments from the Association of the British Pharmaceutical Industry and from patient groups. Any appropriate revisions to the recommendations will be made in the light of this information.